Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?

Shares of Sarepta Therapeutics (SRPT) have gained 14.1% over the past four weeks to close the last trading session at $124.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $184.15 indicates a potential upside of 48%.The average comprises 20 short-term price targets ranging from a low of $75 to a high of $217, with a standard deviation of $32.08. While the lowest estimate indi ...